𝔖 Bobbio Scriptorium
✦   LIBER   ✦

9069 A risk–benefit analysis according to age using pooled data from two phase II trials of cisplatin plus S-1 for non-small-cell lung cancer in Japan

✍ Scribed by Sakai, H.; Yamamoto, N.; Ichinose, Y.; Kubota, K.; Gemma, A.; Saijo, N.; Fukuoka, M.; Niitani, H.


Book ID
121936989
Publisher
Elsevier Science
Year
2009
Tongue
English
Weight
66 KB
Volume
7
Category
Article
ISSN
1359-6349

No coin nor oath required. For personal study only.